Impact of a Hospital Pharmacist's Intervention on FENO (Fractional Exhaled Nitric Oxide) in Asthmatic Patients

University of Liege

Status

Completed

Conditions

Asthma

Treatments

Other: Questionnaires for control group

Other: Pharmacist's intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT03093363

B707201629850

Details and patient eligibility

About

The impact of a pharmacist's intervention on asthma control has now been well demonstrated, but its effect on inflammatory markers of FENO (Fractional exhaled nitric oxide) in asthmatic patients has been little studied in the literature. The aim of this study is to investigate the impact of a pharmacist's intervention on FENO in patients seen in clinical practice by a pneumologist in a secondary university center.

Enrollment

68 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult asthmatics (definition of asthma: FEV1 [forced expiratory volume in 1 second] reversibility of at least 12% and 200 mL after 400 mcg of salbutamol and/or PC20M [provocative concentration of methacholine causing a 20% fall in FEV1]<16 mg/mL)
unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist at the visit
FENO (fractional exhaled nitric oxide) > or = 25 ppb

Exclusion criteria

Treatment with oral corticosteroids to treat an asthma exacerbation within 4 weeks before the visit with the pneumologist

Exclusion Criteria during the study:

Change of the dose of ICS (inhaled corticosteroids) during the follow-up of 3 months after the pharmacist's intervention
Severe asthma exacerbation requiring oral corticosteroids within the 4 weeks before the follow-up visit (3 months after the pharmacist's intervention)